Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Non-COVID-19 Acute Respiratory Distress Syndrome

Summary

This is a Phase 2 randomized study to assess the safety and efficacy of COVI-MSC in the setting of current standard of care treatments for subjects hospitalized subjects with acute respiratory distress syndrome not related to COVID-19 infection.

Timeline

Start

2021-09

Primary completion

2022-02

Completion

2022-04

Outcome

Outcome not reported

Stopped: “Replaced by a different protocol.”

Drugs

Indications